Clinical trial
Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor…
NCT00421031 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00421031 |
|---|---|
| Title | Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause |
| Official title | A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of DVS-233 SR For Relief of Vasomotor Symptoms Associated With Menopause |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Vasomotor Symptoms |
| Intervention type | Drug |
| Interventions | DVS-233 SR |
| Enrollment | 540 |
| Start date | Dec 1, 2003 |
| Completion | Apr 1, 2004 |
| First posted | Jan 11, 2007 |
| Last update posted | Jan 11, 2007 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: